BAUSCH HEALTH COMPANIES WKN: A2JQ1X ISIN: CA0717341071 Forum: Aktien Thema: Hauptdiskussion

Diese Aktie wird noch viel weiter fallen nach cnbc Urteil

hier wurde manipuliert...die meisten Fonds sind raus...

Okay letztes Jahr :-)

Krass wo die Aktie mal war vor ein paar Jahren. Crazy wo diese jetzt ist.

Habe mir 55 Stück für 33 EKG geholt.

Warte bis auf 30 Euro

Wahnsinn...alle Analysten-Ratings deutlich über 100$. Das Portfolio proppevoll, Zahlen lange nicht so schlecht dass 12Milliarden Bürsenwertverlust gerechtfertigt sind! Interessiert aber momentan nicht! Ich setze auf Rebound vom jetzigen Niveau!

Wenn Du in ein fallendes Messer greifen willst :)

Sollte man jetzt einsteigen??

Hab kurz überlegt stehen aber Manipulationen im Raum..

Die Aktien des Pharmakonzerns Valeant verbilligen sich an der NYSE um zeitweise rund 40 Prozent ein. Das kanadische Unternehmen, gegen das in den USA wegen seiner Bilanzpraktiken ermittelt wird, hat wegen Verzögerungen bei der Veröffentlichung des Jahresberichts vor einem Zahlungsausfall gewarnt.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.30-1.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.66, AnalystRatingsNetwork.com reports. The company issued revenue guidance of $2.3-2.4 billion, compared to the consensus revenue estimate of $2.85 billion.Valeant Pharmaceuticals Intl also updated its FY16 guidance to $9.50-10.50 EPS. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) opened at 69.04 on Tuesday. Valeant Pharmaceuticals Intl Inc has a 12-month low of $59.87 and a 12-month high of $263.81. The stock’s 50 day moving average is $81.88 and its 200 day moving average is $120.54. The company has a market cap of $23.69 billion and a P/E ratio of 39.66. Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its quarterly earnings data on Tuesday, March 15th. The specialty pharmaceutical company reported $2.50 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.61 by $0.11. During the same period last year, the company earned $2.58 earnings per share. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.75 billion. The firm’s quarterly revenue was up 22.3% compared to the same quarter last year. On average, equities analysts forecast that Valeant Pharmaceuticals Intl Inc will post $10.27 earnings per share for the current year. VRX has been the subject of several research reports. Mizuho reissued a neutral rating and set a $112.00 price objective (down previously from $130.00) on shares of Valeant Pharmaceuticals Intl in a research report on Sunday, January 3rd. Vetr raised shares of Valeant Pharmaceuticals Intl from a buy rating to a strong-buy rating and set a $122.73 price objective for the company in a research report on Tuesday, December 29th. TD Securities downgraded shares of Valeant Pharmaceuticals Intl from a buy rating to a hold rating and lowered their price objective for the stock from $155.00 to $110.00 in a research report on Monday, February 29th. Jefferies Group reissued a buy rating and set a $106.00 price objective (down previously from $172.00) on shares of Valeant Pharmaceuticals Intl in a research report on Monday, February 29th. Finally, CIBC initiated coverage on shares of Valeant Pharmaceuticals Intl in a research report on Monday, November 30th. They set a sector perform rating and a $90.00 price objective for the company. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $134.68. Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

ua schwacher Ausblick

niemand ist Hellseher

Das hättst du lieber gelassen.

Bisschen zocken,mal 100 zu 52€ ins depot gepackt